Since the recent publication of data showing favorable outcomes for patients with HIV-1 and ESRD, kidney transplantation has become a therapeutic option in this population. However, reports have documented unexplained reduced allograft survival in these patients. We hypothesized that the unrecognized infection of the transplanted kidney by HIV-1 can compromise long-term allograft function. Using electron microscopy and molecular biology, we examined protocol renal transplant biopsies from 19 recipients with HIV-1 who did not have detectable levels of plasma HIV-1 RNA at transplantation. We found that HIV-1 infected the kidney allograft in 68% of these patients. Notably, HIV-1 infection was detected in either podocytes predominately (38% of recipients) or tubular cells only (62% of recipients). Podocyte infection associated with podocyte apoptosis and loss of differentiation markers as well as a faster decline in allograft function compared with tubular cell infection. In allografts with tubular cell infection, epithelial cells of the proximal convoluted tubules frequently contained abnormal mitochondria, and both patients who developed features of subclinical acute cellular rejection had allografts with tubular cell infection. Finally, we provide a novel noninvasive test for determining HIV-1 infection of the kidney allograft by measuring HIV-1 DNA and RNA levels in patients' urine. In conclusion, HIV-1 can infect kidney allografts after transplantation despite undetectable viremia, and this infection might influence graft outcome.
More than 30 years after the first description of AIDS, kidney disease remains an important contributor to morbidity and mortality among HIV-infected patients. 1, 2 The introduction of highly active antiretroviral therapy (HAART) 15 years ago has completely changed the prognosis of HIV-infected patients, significantly reducing mortality and increasing life expectancy. 3 However, ESRD remains common in this population. 2 Indeed, HIV represents the third most common cause of ESRD among African Americans aged ,65 years, and approximately 900 HIV-infected patients per year start dialysis in the United States. 2 The kidney lesions that develop during HIV infection are primarily due to a particularly aggressive form of FSGS called HIV-associated nephropathy (HIVAN). This disease is directly related to the infection of kidney cells by HIV. 2, 4 Until recently, long-term dialysis was the only treatment available for this group of patients and was associated with a poor prognosis. Since the recent publication of reports showing favorable outcomes, kidney transplantation has become a therapeutic option for these patients. [5] [6] [7] Most centers have defined eligibility criteria for transplantation such as a CD4 count .200 cells/ml and an undetectable plasma level of HIV RNA. 8 When using these criteria, the survival rate of HIV-infected transplant recipients is similar to that of non-HIV-infected transplant recipients, but intriguingly, the 3-year allograft survival rate is reduced among the HIV-infected transplant recipients. 5 The mechanisms responsible for this reduced allograft survival rate are unknown, and at least two explanations are usually suggested. 5 The first explanation is the poorly understood high rate of acute cellular rejection observed early after transplantation. The second explanation is the greater exposure to calcineurin inhibitor blood levels due to pharmacokinetic interactions with some antiretroviral drugs. Nevertheless, these explanations do not completely explain the observations, and very little attention has been paid to the potential role of infection of the kidney allograft by HIV, despite the fact that the kidney is a well recognized reservoir for HIV-1 in patients receiving efficient antiretroviral therapy. 9 In 2006, we started to transplant kidneys into HIV-positive patients and observed that few patients had early unexplained allograft dysfunction. We then hypothesized that the unrecognized reinfection of the transplanted kidney by HIV-1 can compromise allograft function.
Using protocol biopsies, electron microscopy, and molecular biology assays, we demonstrate that although plasma HIV-1 RNA is undetectable, HIV-1 infects kidney allografts either asymptomatically or with clinical manifestations, thereby affecting the allograft prognosis. In addition, we developed a new and simple urinary assay to detect the HIV-1 infection in kidneys.
RESULTS

HIV-1 Reinfects Kidney Allografts
During the study period, 939 kidney transplantations were performed in our center. Nineteen of the transplants went to HIV-1-infected patients. We first investigated whether HIV-1 could infect the allograft with undetectable plasma HIV-1 RNA. We performed PCR for HIV-1 DNA in protocol biopsies after transplantation. Surprisingly, we observed that 68% of HIV-1 transplant recipients had detectable HIV-1 DNA in biopsies performed at 3 months after transplantation. Interestingly, HIV-1 DNA remained persistent in biopsies performed at 12 months after transplantation. To determine whether the presence of HIV-1 DNA in the allograft biopsies was caused by infiltrating inflammatory cells or by a true infection of the kidney cells, in situ hybridization (ISH) for HIV-1 RNA was performed in the kidney biopsies. ISH revealed that HIV-1 RNA was detectable in all biopsies. Importantly, we could determine two different forms of allograft infection by HIV-1. In the first group of patients (38% of HIV-1 transplant recipients, n=5), HIV-1 RNA was detectable in the glomeruli and only in very few tubular cells of transplant biopsies at 3 and 12 months after transplantation ( Figure 1A , Supplemental Figure 1) . The positive cells were outlying glomerular cells with morphologic features typical of podocytes ( Figure 1A , Supplemental Figure 1 ). Interestingly, the rate of positive glomeruli for ISH at 3 months was 21.1%64% and increased to 36.9%66% at 12 months. In the second group of patients (62% of HIV-1 transplant recipients, n=8), HIV-1 RNA was detectable only in tubular cells and some vascular sections but not in glomeruli of transplant biopsies performed at 3 and 12 months after transplantation ( Figure 1 , B and C, Supplemental Figure 1 ). ISH showed also positive infiltrating cells at 3 and 12 months after transplantation in 25% (n=2) of patients in the latest group ( Figure 1D, Supplemental Figure 1 ). We therefore concluded that HIV-1 is able to infect kidney allografts even when the level of plasma HIV-1 RNA is undetectable.
Distinct Clinical Features and Allograft Outcome
We then evaluated the clinical characteristics and transplant biopsies of the different patient groups. We observed that patients in the first group (i.e., with podocyte infection) developed nephrotic-range proteinuria early after transplantation (between day 15 and 3 months after transplantation) ( Figure 2A ). Demographic characteristics of these patients are presented in Table 1 . Transplant biopsies performed for each patient at the onset of proteinuria revealed normal histology as determined by light microscopy and no deposit of Igs or complement proteins by immunofluorescence ( Figure  2B ). However, electron microscopy revealed effacement of the podocyte foot processes and vacuolization of the podocyte cytoplasm ( Figure 2 , C and D). To note, before we had ISH results, we initiated our current therapeutic protocol for recurrent FSGS in the first two patients 10 without any improvement of the proteinuria (Figure 2A , patients 1 and 2). Subsequent biopsies performed at 3 and 12 months after transplantation in the group with podocyte infection (patients 1-5) revealed progressive constitution of FSGS lesions in all patients ( Figure 2E ). In addition, electron microscopy revealed the presence of tubuloreticular inclusions within the cytoplasm of endothelial cells (Figure 2 , F-H). These inclusions consist of structures located within the dilated cisternae of the endoplasmic reticulum and are frequently, but not specifically, observed during HIVAN. 11 Finally, these patients had a rapid decline in renal function ( Figure 2A ) and 40% (n=2) reached ESRD in the first 3 years of transplantation.
Demographic characteristics and post-transplantation outcomes of the second group of patients, with only tubular and vascular cell infection by HIV-1, are listed Table 2 and Supplemental Figure 2 . Interestingly, optical analysis of transplant biopsies at 3 and 12 months after transplantation did not show significant abnormalities and electron microscopy revealed that the epithelial cells of the proximal convoluted tubules frequently contained abnormal mitochondria (Figure 2 , J-K). However, patients with infiltrating positive ISH cells on biopsies performed at 3 months after transplantation had features of subclinical acute cellular rejection. In this setting, before we had ISH results, we treated these individuals infiltrate with high-dose steroids. Interestingly, these infiltrates remained persistent on biopsies performed at 12 months after transplantation. In this group, only 12% of participants (n=1) reached ESRD during the early follow-up.
To note, we explored the presence of other viruses (e.g., cytomegalovirus, BK virus, and hepatitis) in all patients and failed to detect any of these viruses in biopsy samples.
Podocyte Depletion
Because podocyte infection by HIV-1 seems to be more severe, we next aimed to better characterize the mechanisms underlying the high rate of allograft failure in this group. In rodents, podocyte depletion is associated with the development of FSGS lesions. 12 We therefore monitored the number of podocytes in the different patient groups. We observed that the number of Wilms tumor protein 1 (WT1)-positive cells was dramatically reduced in patients with podocyte infection at 12 months after transplantation, whereas the count of WT1-positive cells was not affected in patients with tubular cell infection ( Figure 3A) . Importantly, transmission electron microscopy revealed the presence of many apoptotic podocytes only in patients with podocyte infection (Figure  3 , E-G). To characterize podocyte differentiation, we next explored the expression of different podocyte proteins. Interestingly, we observed that compared with the groups of HIV-1 transplantation recipients without proteinuria, transplantation recipients with HIV-1 with podocyte infection had reduced expression of podocin, nephrin, and synaptopodin at 12 months after transplantation, suggesting a state of dedifferentiation (Figure 3, B-D) . Finally, analysis of the protocol biopsies performed 3 months after transplantation revealed that these events appeared quite early after transplantation as podocyte rarefaction and reduced expression of podocyte proteins was already detectable (Supplemental Figure 3) .
Risk Factors for Graft Infection
We next explored whether any risk factors for graft infection could be identified. Analysis of the demographic characteristics revealed no significant differences between patients with podocyte or tubular cell reinfection and patients without any reinfection (Tables 1-3 ). The G1 and G2 haplotypes in the APOL1 gene were recently identified as risk factors for the development of HIVAN in African Americans. 13 APOL1 encodes a protein component of HDL that has trypanolytic activity. We explored whether the APOL1 variants in donors and transplant recipients could explain the recurrence rate and tissue distribution of reinfection. Although the allele frequencies of the three single-nucleotide polymorphisms (SNPs) in African patients was similar to those described in AfricanAmerican patients with HIVAN, 14 we did not observe any correlation between the APOL1 genotype and reinfection of the kidney allograft by HIV-1 (Table 4) .
We then tested whether HIV coreceptor tropism could predict recurrence. For each patient, virus tropism of the C-C chemokine receptor type 5 and C-X-C chemokine receptor type 4 was determined. No significant differences were observed between patients with or without recurrence (Table 5) .
Finally, a SNP 35 kb upstream of the HLA-C locus (rs9264942) was recently shown to be associated with viral load control in a recent genome-wide association study, 15 and this SNP correlates with the level of HLA-C cell surface protein expression. 16 Therefore, we tested whether this SNP would be helpful in predicting recurrence. Unfortunately, no significant differences were observed in patients with or without reinfection (Table 6 ).
Predictive Urinary Test for Infection
Considering the high incidence of allograft infection and the difficulty of performing routine ISH, we thought that the development of a noninvasive diagnostic test for HIV-1 renal allograft infection would be of considerable value. To this end, we performed quantitative PCR of HIV-1 RNA and HIV-1 DNA in urine. We collected urine samples from patients just before protocol biopsies (3 and 12 months after transplantation) and biopsies for cause. After the fresh urine was centrifuged, RNA was extracted from the supernatant and the level of HIV-1 RNA was quantified. The pellets were used for DNA extraction. Sequentially collected urine samples showed that HIV-1 RNA and/or HIV-1 DNA were detectable only in the group of patients with an HIV-infected allograft. Importantly, the presence of HIV-1 RNA and/or HIV-1 DNA in the urine was strictly associated with positive ISH results for the biopsies (Table 7) . Moreover, in some of these biopsies, we observed positive ISH tubular cells sloughing into the tubular lumen (Supplemental Figure 4) . HIV-1 RNA and DNA were detectable at 3 months after transplantation and persisted at 12 months. Furthermore, to exclude any positivity due to infiltrating leukocytes, we performed hematoxylin and eosin staining and CD3 and CD68 immunostaining on cells isolated from the pellet, and we did not observe the presence of inflammatory cells (not shown). Finally, we tried to figure out why some patients develop podocytes or tubular epithelial cells infection by comparing the virus sequences obtained from the urine, but the low viral load did not allow us to succeed in virus sequences.
DISCUSSION
Here we demonstrate that HIV-1 can reinfect kidney epithelial cells after transplantation, even though plasma HIV-1 RNA is undetectable. Importantly, we describe two different forms of allograft infection. In the first case, podocytes are the main target of HIV-1 and infection is associated with nephroticrange proteinuria, progressive development of FSGS, and poor transplant outcome. In the second case, HIV-1 can infect tubular cells from the kidney allograft with fewer clinical manifestations. Finally, we provide a new tool to easily and noninvasively assess transplant kidney cell reinfection by the virus.
Infection of the kidney allograft while viral replication was undetectable in plasma was an unexpected finding. Indeed, all of these HIV-1 patients were registered on the transplant list as patients with controlled disease and thus were expected to benefit from kidney transplantation. Interestingly, the development of HIV nephropathy on native kidneys in patients with undetectable viremia was previously described in several studies. [17] [18] [19] [20] [21] Furthermore, several studies involving HIV-1 transplant kidney recipients have also reported the occurrence of HIVAN in few patients without detectable viremia. 5, 6 How the virus reinfects kidney cells soon after kidney transplantation is an unsolved issue because repeated blood samples failed to detect viremia; however, we have a few hypotheses. Indeed, we cannot exclude that transient episodes of viremia may likely occur (HIV-1 blips) even in patients with successful viral suppression. 22 We also hypothesize that the virus could be directly transfected from recipient-infected T cells to donor kidney cells, as was recently shown in vitro. 23 Of note, it is still unclear how HIV-1 enters in podocytes and tubular cells because no HIV-1 receptors have been described in the kidney. 2 Finally, it remains possible that kidney infection could be the consequence of immunosuppressive drugs and/or insufficient HAART with suboptimal antiretroviral diffusion in the graft.
Due to the small number of patients in our study, we were unable to establish the particular factors that either favor allograft reinfection or determine the surprising dichotomy of nephron segment reinfection (i.e., podocytes versus tubular cells). We provide evidence that transplant reinfection by HIV-1, at least in podocytes, shortens the allograft survival rate. Interestingly, we did not observe any HIVAN on the allografted kidney, whereas most of the recipients developed these collapsing lesions on native kidneys. In fact, we observed here that HIV-1 infection in podocytes was associated with podocyte dedifferentiation, assessed by the loss of specific markers (podocin, synaptopodin, and nephrin), apoptosis, and development of FSGS lesions. Interestingly, this sequence of events is observed in different models of podocyte injury leading to the development of FSGS. 12, 24, 25 The exact mechanism is unknown, but certainly the genetic background of the donor and others parameters may affect the course of glomerular lesions. Indeed, on native kidneys, HIVAN has been linked to G1 and/or G2 APOL1 variants present in the AfricanAmerican population, 13 whereas Caucasians, who do not express these variants, display other various forms of glomerular lesions but usually have no features of HIVAN. Consistently, we observed that 87.5% of our African-African recipients that developed HIVAN on native kidneys displayed either a G1 and/or G2 APOL1 polymorphism, but none of our Caucasian recipients did. Importantly, we found a very low rate of the APOL1 polymorphism in our donor cohort, suggesting that donor APOL1 may play a local role in HIVAN pathophysiology, as was also suggested by the recent report of kidney APOL1 expression in normal and pathologic conditions. 26 Besides genetic predisposition, we cannot exclude that immunosuppressive drugs, by either interacting with the immune system or directly with podocytes (calcineurin inhibitors 27 and steroids 28 ), may modify the classical pattern of kidney lesions observed with HIV-1.
Tubular reinfection seems to have less functional effect in our cohort, but the follow-up is certainly too short. We cannot exclude that tubular cell infection contributes to the shortened allograft survival observed in previous reports. A high rate of acute cellular rejection has been described in renal allografts of this patient population. Here, we observed that the two patients who developed what we called acute cellular rejection had ISH results showing the presence of HIV-1 RNA either in infiltrating leukocytes or in adjacent tubular cells. Persisting virus in infiltrating inflammatory cells (whereas plasma HIV-1 RNA is undetectable) was previously described 29 ; however, the infiltration of inflammatory cells could be the result of an immune reaction against tubular cells infected by HIV-1. Therefore, we hypothesize that the high rate of acute cellular rejection To facilitate monitoring of transplant infection with HIV-1, we provide evidence that the detection of HIV-1 DNA, and RNA in urine samples by quantitative PCR seems to be a consequence of kidney cell infection. Indeed, urinary HIV-1 DNA and/or HIV-1 RNA were exclusively detected in patients with positive RNA ISH either in podocytes or in tubular cells. Furthermore, light microscopy examination and immunocytochemistry of urine pellets exclude that HIV-1 DNA and/or HIV-1 RNA derived from infiltrating inflammatory cells. We cannot formally exclude that HIV-1 could be filtered from the plasma into the urine, even in the absence of detectable viremia; however, its detection only in the setting of a positive ISH in the graft supports our hypothesis.
In conclusion, our work reveals the capacity of HIV-1 to infect the kidney allograft despite undetectable viremia. Urine testing appears to be a promising noninvasive method of diagnosing HIV-1 reinfection, although it remains to be confirmed in a larger cohort. Finally, our data strongly support the need for close proteinuria monitoring in assessing the outcome of HIV-infected kidney transplant recipients. , had undetectable plasma HIV RNA levels (,50 copies/ ml), and had been stable on HAART for at least 6 months. Patients with stage C HIV (according to the US Centers for Disease Control and Prevention classification) were also included in the program, with the exception of those patients with a previous history of progressive multifocal leukoencephalopathy, primary central nervous system lymphoma, or visceral Kaposi's sarcoma.
CONCISE METHODS
Patients
The immunosuppressive regimen was similar for all patients and included steroids, tacrolimus, and mycophenolate mofetil. Induction therapy was performed with the anti-IL-2 receptor antibody basiliximab for all patients except those with preformed donor-specific antibodies, for whom the induction therapy was changed to rabbit antithymocyte globulin. In the particular case of sensitized patients, intravenous Ig was added. The trough levels of tacrolimus were carefully monitored due to pharmacokinetic drug interactions. The antiretroviral drugs doses were adjusted based on kidney function, with frequent adjustments required particularly during the early post-transplantation period and during periods of graft dysfunction.
The antiretroviral combination therapy was similar for all patients and consisted of two nucleoside analog reverse-transcriptase inhibitors and one protease inhibitor. All patients continued their HAART regimen after transplantation and for the entire follow-up period. All patients with a functioning allograft underwent protocol biopsies at 3 and 12 months after transplantation. Furthermore, in the case of ARF and/or proteinuria, a transplant biopsy was performed.
Renal Function
The serum creatinine level was measured monthly during the first year and every 3 months thereafter using a Synchron Cx4 autoanalyzer (Beckman Coulter). The GFR was estimated using the Modification of Diet in Renal Disease study formula. 30 
Biopsy Samples and Morphologic Analyses
Transplant kidney biopsy specimens were fixed in alcohol-formalinacetic acid solution and embedded in paraffin. Four-micrometer sections were stained with periodic acid-Schiff, Masson's trichrome, and hematoxylin and eosin. Electron microscopy analyses were performed as previously described. 31 
Immunohistochemistry and Immunofluorescence
Four-micrometer sections of paraffin-embedded kidneys were incubated with anti-nephrin antibody (Progen), anti-WT1 antibody (Dako), anti-podocin antibody (Sigma-Aldrich) and anti-synaptopodin antibody (Novus Biologicals). The primary antibodies were revealed with the appropriate Alexa 488-or Alexa 555-conjugated secondary antibodies (Molecular Probes). Immunofluorescence staining was visualized using the Zeiss LSM 700 confocal microscope. The podocyte-stained area was automatically quantified using a Nikon digital camera Dx/m/1200 and ImageJ software and expressed as the percentage of the podocyte-stained area upon the total glomerular area. All glomerular sections per biopsy were quantified. The plasma HIV-1 RNA level was quantified as previously described using the COBAS AmpliPrep/COBAS TaqMan HIV-1 RT-PCR assay (version 2.0; Roche Diagnostics), which has a detection limit of 20 copies/ml. The level of cellassociated HIV-1 DNA was quantified using whole-blood samples and a real-time HIV-1 DNA assay 32 (Biocentric) that has a detection limit of 1.7 log copies/10 6 cells. Plasma HIV-1 RNA levels were determined on days 0 and 7 and then monthly until 6 months after transplantation. 33 The HIV-1 RNA levels were monitored every 3 months thereafter.
HIV-1 DNA Detection in Frozen Biopsy Samples
Total DNAwas extracted from renal tissues using the QIAamp tissue kit (Qiagen) according to the manufacturer's instructions. The level of cellassociated HIV-1 DNA was quantified using a real-time HIV-1 DNA assay 32 (Biocentric).
ISH
Alcohol-formalin-acetic acid solution-fixed, paraffin-embedded tissues were assayed for HIV-1 RNA expression using a previously described digoxygenin-antidigoxygenin technique. 34 The A1  A2  B1  B2  DR1  DR2  DQ1  DQ2  A1  A2  B1  B2  DR1  DR2  DQ1  DQ2   With podocyte infection  1  2  0  1 5  5 1  3  8  0  0  1  2  5 1  8  3  8  2  4  2  2  26  15  44  7  15  2  6  3  30  63  13  7  0  2  0  3  23  30  7  44  15  16  6  5  2  0  38  44  13  15  6  0  4  2  24  53  81  7  8  2  7  1  3  18  57  7  8  3  4  5  2  2  18  58  7  13  2  5  1  2  51  8  17  4 With podocyte infection 1 digoxigenin-UTP-labeled riboprobe that was used spans the whole genome of HIV-1 (Lofstrand Labs Ltd). Nitroblue tetrazolium-5-bromo-4-chloro-3-indolyl phosphate toluidinium was used to visualize infected cells in the tissues. The specificity of the hybridization signal was systematically checked by hybridizing sense probes with parallel sections and antisense probes with uninfected renal tissues. ISH-stained tissues were visualized and photographed with an Olympus Proxis microscope and a Zeiss AxioCam ICc1 camera. For each biopsy, we determined the number of positive glomeruli in all fields of the section, which are expressed as the number of positive glomeruli for the total number of glomeruli.
Urine Collection and HIV-1 RNA/DNA Testing Urine samples were collected longitudinally for each patient at 3 and 12 months after transplantation and when a biopsy for cause was performed. Fifty milliliters of freshly collected urine was immediately centrifuged at 10003g for 10 minutes at 4°C. RNA was extracted from 3.2 ml of supernatant using a Qiagen kit, and the level of HIV-1 RNA was quantified using a Biocentric ultrasensitive assay. Pellets were used for DNA extraction with the Qiagen QIAamp DNA mini kit according to the manufacturer's instructions. The level of HIV-1 DNA was then quantified using an ultrasensitive assay from Biocentric. 32,33
HIV-1 Coreceptor Analyses
The coreceptor usage of viruses was determined using the SVM Geno2pheno algorithm (available at http://coreceptor.bioinf. mpi-sb.mpg.de/cgi-bin/coreceptor.pl) with a 10% false positive rate.
APOL1 SNP Genotyping
PCR amplification of the end of APOL1 exon 6 was performed for all individuals with the following primers: forward, 59-39AAG CGG TGA ACA GGT GGA GA; and reverse, 59-39CCC CTG CCA GGC ATA TCT CT. Sequencing was performed using a Big Dye terminator cycle sequencing kit and an ABI Prism 3130 XL DNA analyzer (Life Technologies). Direct Sanger sequencing allowed the detection of three SNPs: the two missense variants p.Ser342Gly and p.Ile384Met (rs73885319 and rs60910145) called the G1 risk allele and the 6 bp deletion p.del Asn388/Tyr389 (rs71785313) called G2. Written informed consent was obtained from each patient.
HLA-C -35 SNP Genotyping
PCR amplification of rs9264942 variant, localized 35 kb upstream of the HLA-C gene, was performed for all individuals with the primers forward (GTC CCA ATT CCT TGA TTC AGT) and reverse (GTG GAG ATT CCT GCT GTG). Sequencing was carried out using a Big Dye terminator cycle sequencing kit and was analyzed with an ABI Prism 3130 XL DNA analyzer (Life Technologies).
Statistical Analyses
The data were expressed as the mean6SD. Differences among the experimental groups were evaluated using ANOVA, followed by the Tukey-Kramer test when significant. When only two groups were compared, the Mann-Whitney test was used. P values ,0.05 were considered statistically significant. Analyses were performed with GraphPad Prism 5 software. Without allograft infection  14  CCR5  15  CCR5  16  CCR5  17  CXCR4  18  CCR5  19  CCR5 CCR5, C-C chemokine receptor type 5; CXCR4, C-X-C chemokine receptor type 4; ND, not determined. Table 6 . HLA-C-35 SNP genotyping T T  7  C T  T T  8  T T  C T  9  C T  C T  10  TT  CT  11  CC  TT  12  TT  TT  13  TT  TT  Without allograft infection  14  CC  TT  15  CC  TT  16  CT  CT  17  TT  CC  18  CT  CT  19 TT CC ND, not determined. 
